InterPAD - DETAILS

cabergoline, 81409-90-7, Dostinex, Cabaser, Cabergolina, Cabergolinum, Cabergolinum [Latin], Cabergolina [Spanish], FCE-21336, Velactis, FCE 21336, Caberlin, UNII-LL60K9J05T, 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, BRN 6020775, CHEBI:3286, LL60K9J05T, DTXSID6022719, Cabaseril, DTXCID502719, Cabergoline [USAN:USP:INN:BAN], 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea, MFCD00867887, Cabergolinum (Latin), 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea, (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, CABERGOLINE (MART.), CABERGOLINE [MART.], CABERGOLINE (USP-RS), CABERGOLINE [USP-RS], (6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide, (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide, Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-, Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, CABERGOLINE (EP MONOGRAPH), CABERGOLINE [EP MONOGRAPH], Sogilen, CABERGOLINE (USP MONOGRAPH), CABERGOLINE [USP MONOGRAPH], Cabergoline (USAN:USP:INN:BAN), CABERGOLINE (EMA EPAR VETERINARY), CABERGOLINE [EMA EPAR VETERINARY], Dostinex (TN), (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide, 1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea, Cabaser (TN), CAS-81409-90-7, SR-05000001493, (8R)-6-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)ergoline-8-carboxamide, 1-((6-allylergoline-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, 1-[(6-allylergolin-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea, NCGC00167821-01, (8beta)-N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-ergoline-8-carboxamide, (8beta)-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide, Cabergoline; 1-Ethyl-3-[3-(dimethylamino)propyl]-3-[[(6aR,9R,10aR)-7-(prop-2-enyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]carbonyl]urea, CG-101, CABERGOLINE [MI], CABERGOLINE [INN], CABERGOLINE [JAN], CABERGOLINE [USAN], GTPL37, CABERGOLINE [VANDF], SCHEMBL42292, CABERGOLINE [WHO-DD], BIDD:GT0775, Cabergoline (JAN/USP/INN), CHEMBL1201087, Cabergoline, >=98% (HPLC), CABERGOLINE [ORANGE BOOK], G02CB03, N04BC06, KORNTPPJEAJQIU-KJXAQDMKSA-N, HMS2090A09, HMS3886H05, Tox21_112589, BDBM50426497, s5842, 1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea, AKOS015961587, Tox21_112589_1, DB00248, NCGC00344544-01, (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide, AC-26126, Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-, HY-15296, MS-28208, Cabergoline 1000 microg/mL in Acetonitrile, NS00001091, C08187, D00987, F17353, AB01275484-01, EN300-19767804, Q423308, SR-05000001493-1, SR-05000001493-2, BRD-K86882815-001-01-6, Cabergoline, European Pharmacopoeia (EP) Reference Standard, Cabergoline, United States Pharmacopeia (USP) Reference Standard, 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, 6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide, N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide, (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide, (9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide, 1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carbonyl]urea, ERGOLINE-8.BETA.-CARBOXAMIDE, N-(3-(DIMETHYLAMINO)PROPYL)-N-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-

Name	Cabergoline
PubChem CID	54746
Molecular Weight	451.6g/mol
Synonyms	cabergoline, 81409-90-7, Dostinex, Cabaser, Cabergolina, Cabergolinum, Cabergolinum [Latin], Cabergolina [Spanish], FCE-21336, Velactis, FCE 21336, Caberlin, UNII-LL60K9J05T, 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, BRN 6020775, CHEBI:3286, LL60K9J05T, DTXSID6022719, Cabaseril, DTXCID502719, Cabergoline [USAN:USP:INN:BAN], 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea, MFCD00867887, Cabergolinum (Latin), 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea, (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide, CABERGOLINE (MART.), CABERGOLINE [MART.], CABERGOLINE (USP-RS), CABERGOLINE [USP-RS], (6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide, (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide, Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-, Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, CABERGOLINE (EP MONOGRAPH), CABERGOLINE [EP MONOGRAPH], Sogilen, CABERGOLINE (USP MONOGRAPH), CABERGOLINE [USP MONOGRAPH], Cabergoline (USAN:USP:INN:BAN), CABERGOLINE (EMA EPAR VETERINARY), CABERGOLINE [EMA EPAR VETERINARY], Dostinex (TN), (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide, 1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea, Cabaser (TN), CAS-81409-90-7, SR-05000001493, (8R)-6-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)ergoline-8-carboxamide, 1-((6-allylergoline-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea, 1-[(6-allylergolin-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea, NCGC00167821-01, (8beta)-N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-ergoline-8-carboxamide, (8beta)-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide, Cabergoline; 1-Ethyl-3-[3-(dimethylamino)propyl]-3-[[(6aR,9R,10aR)-7-(prop-2-enyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]carbonyl]urea, CG-101, CABERGOLINE [MI], CABERGOLINE [INN], CABERGOLINE [JAN], CABERGOLINE [USAN], GTPL37, CABERGOLINE [VANDF], SCHEMBL42292, CABERGOLINE [WHO-DD], BIDD:GT0775, Cabergoline (JAN/USP/INN), CHEMBL1201087, Cabergoline, >=98% (HPLC), CABERGOLINE [ORANGE BOOK], G02CB03, N04BC06, KORNTPPJEAJQIU-KJXAQDMKSA-N, HMS2090A09, HMS3886H05, Tox21_112589, BDBM50426497, s5842, 1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea, AKOS015961587, Tox21_112589_1, DB00248, NCGC00344544-01, (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide, AC-26126, Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-, HY-15296, MS-28208, Cabergoline 1000 microg/mL in Acetonitrile, NS00001091, C08187, D00987, F17353, AB01275484-01, EN300-19767804, Q423308, SR-05000001493-1, SR-05000001493-2, BRD-K86882815-001-01-6, Cabergoline, European Pharmacopoeia (EP) Reference Standard, Cabergoline, United States Pharmacopeia (USP) Reference Standard, 1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)-propyl]-3-ethylurea, 6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide, N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide, (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide, (9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide, 1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carbonyl]urea, ERGOLINE-8.BETA.-CARBOXAMIDE, N-(3-(DIMETHYLAMINO)PROPYL)-N-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-
Drug Type	Small molecule
Formula	C₂₆H₃₇N₅O₂
SMILES	CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
InChI	1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
InChIKey	KORNTPPJEAJQIU-KJXAQDMKSA-N
CAS Number	81409-90-7
ChEMBL ID	CHEMBL1201087
ChEBI ID	CHEBI:3286
TTD ID	D04EGX
Drug Bank ID	DB00248
KEGG ID	C08187
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Brusatol, Cabergoline
Partner Name	Brusatol
Disease Info	[ICD-11: 2F37]	Pituitary adenomas		Investigative
Biological Phenomena	Induction-->ROS accumulation
Gene Regulation	Down-regulation	Phosphorylation	EIF4EBP1	hsa1978
	Down-regulation	Expression	RHEB	hsa6009
	Up-regulation	Expression	ROS1	hsa6098
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
In Vitro Model	GH3	Rat pituitary gland neoplasm	Rattus norvegicus (Rat)	CVCL_0273
In Vitro Model	MMQ	Rat pituitary gland neoplasm	Rattus norvegicus (Rat)	CVCL_2117
In Vivo Model	A total of 5×10⁶ of the indicated MMQ and GH3 cells were resuspended in 100 μL PBS buffer mixed with Matrigel (1 : 1) and then subcutaneously injected into the back of each nude mice.
Result	Combined use of CAB and BT may increase the clinical effectiveness of treatment for human pituitary adenomas.